Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2014 07/16/2014 07/17/2014 07/18/2014 07/21/2014 Date
312.15(c) 306.12(c) 296.41(c) 305.92(c) 303.73(c) Last
1 194 626 710 536 832 800 785 178 562 231 Volume
-1.82% -1.93% -3.17% +3.21% -0.72% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
Surperformance© rating of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More about the company
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 748 M
EBIT 2014 1 126 M
Net income 2014 445 M
Finance 2014 1 133 M
Yield 2014 -
Sales 2015 3 410 M
EBIT 2015 1 497 M
Net income 2015 769 M
Finance 2015 2 307 M
Yield 2015 -
PER 2014 79,31
PER 2015 46,61
EV / Sales 2014 10,7x
EV / Sales 2015 8,31x
Capitalization 30 640 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
4d ago REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
4d ago REGENERON PHARMACEUTICALS : to Report Second Quarter 2014 Financial and Operatin..
4d ago REGENERON PHARMACEUTICALS : Two-Year Results From Phase 3 VIVID-DME Trial of EYL..
6d ago REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Results from Phase 2b S..
07/14 REGENERON PHARMACEUTICALS : Assigned Patent
07/14 REGENERON PHARMACEUTICALS : and Sanofi Report Dupilumab Study Results
07/11 SANOFI : Drug affords significant eczema relief: Companies
07/09 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Compositions..
07/09 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Treating Autoimmune Dis..
07/09 NASDAQ 100 MOVERS : Grmn, orly
07/08 NASDAQ 100 MOVERS : Bidu, stx
07/07 NASDAQ 100 MOVERS : Wynn, regn
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
EPS Revisions
Regeneron Pharmaceuticals  : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF